Workflow
科技项目研发费用损失保险
icon
Search documents
让科创星火燃成燎原之势 南京科创金融改革试验区实践纪实
Jin Rong Shi Bao· 2025-11-12 02:05
Core Insights - The establishment of the Science and Technology Innovation Financial Reform Pilot Zone in Nanjing aims to create a demonstration area for financial cooperation, innovation in products and services, and deep integration of industry and city [1] Group 1: Financial Innovations and Support - Nanjing Fangshenghe Pharmaceutical Technology Co., Ltd. has successfully utilized the "Technology Project R&D Expense Loss Insurance," which is the first of its kind in the country, to mitigate R&D risks [2][3] - The company received nearly one million yuan in compensation from the insurance, which helped offset R&D costs [3] - The Industrial and Commercial Bank of China (ICBC) Nanjing Branch developed a new credit rating model for technology companies, allowing Fangshenghe to secure an 85.14 million yuan loan, marking the first loan issued under this new model [4] Group 2: Policy and Regulatory Support - The financial regulatory authority announced a pilot program to relax merger loan policies for technology companies, including Nanjing as one of the pilot cities [5] - The Jiangsu Provincial Government has outlined a clear roadmap for the reform of the Science and Technology Innovation Financial Reform Pilot Zone, with 20 key tasks identified [6] - A quarterly dynamic evaluation mechanism has been established to assess the effectiveness of financial institutions in serving technological innovation [6] Group 3: Investment Trends and Market Dynamics - The robotics industry in Nanjing is emerging as a significant investment hotspot, with companies like Estun Robotics making strides in the field [8][10] - The Jiangsu Nanjing Soft Information Service Industry Special Fund invested 30 million yuan in Estun Cool Technology, which is part of a larger financing goal of 130 million yuan [8][9] - The investment in Estun Cool Technology is the first direct investment project from the provincial strategic emerging industry fund [8] Group 4: Collaborative Financial Models - The "loan + external direct investment" model has been emphasized in Nanjing, allowing banks and investment institutions to collaborate effectively [10] - The establishment of a "see investment, then lend" mechanism has helped banks overcome their hesitance in financing high-tech enterprises [10] - The Jiangsu Provincial Financial Office is exploring a "patent commercialization + equity" model to facilitate the transformation of patent achievements into financial products [11] Group 5: Growth Metrics and Achievements - As of September 2025, the total loan balance for technology enterprises in Nanjing reached 450 billion yuan, a year-on-year increase of 38% [15] - Since the establishment of the pilot zone, 17 new domestic and foreign listed companies have emerged, including five on the Sci-Tech Innovation Board [15] - The total direct financing from newly issued technology innovation bonds exceeded 54 billion yuan [15]
让科创星火燃成燎原之势
Jin Rong Shi Bao· 2025-11-12 01:21
Group 1 - The core idea of the news is the establishment and development of the Nanjing Science and Technology Financial Reform Pilot Zone, which aims to create a demonstration area for science and technology finance, innovative product business aggregation, and deep integration of industry and city [2][3][8] - The pilot zone has seen significant achievements in promoting technology finance from "experiment" to "demonstration," with various financial institutions and enterprises growing together [3][9] - The Nanjing government and financial regulatory bodies have implemented multiple measures to support the pilot zone, including the introduction of specialized financial products and services for technology enterprises [8][14] Group 2 - Nanjing Fangshenghe Pharmaceutical Technology Co., Ltd. has successfully navigated financing challenges by utilizing innovative insurance products, such as the "R&D Expense Loss Insurance," which is the first of its kind in the country [4][5][6] - The company has received nearly 100 million yuan in compensation from insurance, effectively mitigating R&D risks and allowing for further investment in other insurance products [5][6] - Fangshenghe's successful acquisition of Li Tail Pharmaceutical was supported by a nearly 100 million yuan merger loan from Industrial and Commercial Bank of China, facilitated by a new evaluation model for technology enterprises [6][7] Group 3 - The Nanjing pilot zone has established a comprehensive financial service system for technology enterprises, with a focus on "policy + product + model" innovation [9][18] - The introduction of the "investment-loan linkage" model has become a key initiative in promoting technology finance, allowing banks and investment institutions to collaborate effectively [13][17] - By the end of September 2025, the total loan balance for technology enterprises in Nanjing reached 450 billion yuan, marking a 38% year-on-year increase [18]
从“散点创新”迈向“体系搭建” 政企险联手畅通科技企业保障路径
Group 1 - The core viewpoint of the article is that the insurance coverage for technology companies is gradually improving through three main approaches: collaboration with insurance companies to develop customized insurance products, finding suitable products within regulatory frameworks, and utilizing government subsidies for insurance premiums [2][3][9] - Technology companies are increasingly able to secure insurance coverage, alleviating previous difficulties in finding appropriate products due to high risks or costs [2][3] - The collaboration between technology companies and insurance providers is becoming a significant pathway for obtaining insurance, as seen in the case of Huadian Gongxian and Jimei University, which developed a specialized insurance product for research and development expenses [5][6] Group 2 - Local financial regulatory bodies are taking the lead in building a technology insurance product system to address the uncertainties faced by technology companies [7][8] - The Shanghai financial regulatory bureau has established a comprehensive technology insurance product system, which includes a risk protection mechanism for the biopharmaceutical industry, resulting in significant insurance coverage and premium income [7][8] - Government subsidies for technology insurance premiums are being implemented in various regions to reduce the financial burden on small and medium-sized technology enterprises, thereby encouraging them to obtain insurance [9][10]